Novo Nordisk A/S (NVO)
-NYSE 169.55 
1.59(0.93%) May 22, 4:03PM EDT
| Prev Close: | 171.14 |
|---|
| Open: | 172.02 |
|---|
| Bid: | 158.81 x 100 |
|---|
| Ask: | 176.00 x 100 |
|---|
| 1y Target Est: | 199.15 |
|---|
| Beta: | 1.06 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 169.07 - 172.68 |
|---|
| 52wk Range: | 129.41 - 194.44 |
|---|
| Volume: | 323,164 |
|---|
| Avg Vol (3m): | 284,027 |
|---|
| Market Cap: | 91.83B |
|---|
| P/E (ttm): | 23.52 |
|---|
| EPS (ttm): | 7.21 |
|---|
| Div & Yield: | 2.26 (1.30%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Pricing A Highly Probable Takeover Of MannKindat Seeking Alpha(Wed, May 22)
- Positive Data on Novo Nordisk's N9-GPZacks(Tue, May 21)
- Will the FDA Approve Merck's Insomnia Drug?at Motley Fool(Tue, May 21)
- A New Drug Sales Modelat Motley Fool(Mon, May 20)
- Why MannKind's Afrezza Will Succeed Where Pfizer Failedat Seeking Alpha(Sat, May 18)
- Good News For Health Care Stocksat Motley Fool(Fri, May 17)
- Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund, Interviews with The Wall Street Transcript: Investing in Health Care InnovationWall Street Transcript(Thu, May 16)
- Will Obesity Drugs Gain Soon?at Motley Fool(Wed, May 15)
- What Does This Failure Mean for Eli Lilly Investors?at Motley Fool(Tue, May 14)
- Does the Healthcare Industry mean Stability?at Motley Fool(Tue, May 14)
- Novo Nordisk Rapidly Raising Dividendat Investor's Business Daily(Tue, May 14)
- Why This Stock's Crash is a Buying Opportunityat Motley Fool(Tue, May 14)
- The Ups and Downs of Diabetesat Motley Fool(Wed, May 8)
- 3 Stocks Improving Performance Of The Health Care Sectorat TheStreet(Mon, May 6)
- Sixty-One Per Cent of Women Say their Sex Lives are Suffering Due to a Condition of MenopausePR Newswire(Mon, May 6)
Key Statistics
| Forward P/E (1 yr): | 21.04 |
|---|
| P/S (ttm): | 6.65 |
|---|
| Ex-Dividend Date: | 21-Mar-13 |
|---|
Analysts
| Annual EPS Est
(Dec-12)
: | N/A |
|---|
| Quarterly EPS Est
(Jun-12)
: | N/A |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals.
View More